Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Henning Andersen Renato MantegazzaJing Jing WangFanny O'BrienKaushik PatraJames F Howardnull null

Published in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2019)

Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624.

Keyphrases

myasthenia gravis
phase iii
sleep quality
depressive symptoms
study protocol
social support
physical activity
clinical trial
mental health
phase ii
open label
double blind
randomized controlled trial